US$ 23.28
glp 1 study Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database (DEFINE-G) Study finds GLP-1 receptor agonists
Description
E., Pavo, I., et al (2021)

Future regulatory approvals could substantially expand the addressable patient population beyond diabetes and obesity

The long-term administration of lixisenatide has been shown to decrease NHE3 activity in overweight T2D patients
There is no strong clinical evidence favoring morning over evening
